OncoMatch

OncoMatch/Clinical Trials/NCT06366490

Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer

Is NCT06366490 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Innocell Autologous Cellular Immunotherapy for ovarian cancer.

Phase 1RecruitingPhotonPharma, Inc.NCT06366490Data as of Jun 2026

Treatment: Innocell Autologous Cellular ImmunotherapySafety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients with Recurrent Epithelial Ovarian Cancer

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Innocell Autologous Cellular Immunotherapy

Cancer type

Ovarian Cancer

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Female only

Prior therapy

Min 1 prior line

Must have received: platinum-based chemotherapy

has received at least 1 line of platinum-based systemic therapy

Must have received: PARP inhibitor

PARP inhibitors for women with germline BRCA mutation and in homologous recombination repair deficiency based on prior molecular testing

Must have received: VEGF inhibitor (bevacizumab)

bevacizumab as appropriate

Cannot have received: systemic therapy

treatment with an approved systemic therapy within 3 weeks of planned vaccine initiation

Cannot have received: investigational agent

received any other investigational agents within 4 weeks of planned vaccine initiation

Lab requirements

Blood counts

Kidney function

Liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • City of Hope · Duarte, California

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06366490 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior systemic therapy, investigational agent disqualifies patients from enrollment.

Is this trial open to male patients?

No. This trial enrolls female patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify